Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
BioPharma Dive5d
Novo outlines new late-stage study of obesity drug CagriSema
CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...
BioSpace3d
After Unforced Error, Novo Execs Try to Boost CagriSema Sentiment—Without Hard Numbers
Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...
Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss
Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...
pharmaphorum5d
Novo charts course ahead for CagriSema after lacklustre data
Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...
Reuters6d
Novo Nordisk defends next-gen obesity drug CagriSema, details new trial
The company's shares were up 4.2% at 1527 GMT. The CagriSema trial, called REDEFINE-1, is crucial to Novo's drug pipeline as the company loses its first mover advantage with Wegovy and Eli Lilly ...